GHK-Cu reconstitution calculator

Enter your vial amount and target dose. DrawDose returns the BAC water volume, syringe units, and a vial label you can copy.

What GHK-Cu is and how it differs from other peptides

GHK-Cu is the copper(II) complex of glycyl-L-histidyl-L-lysine, a naturally occurring tripeptide first isolated from human plasma albumin by Loren Pickart in 1973. The tripeptide has a strong affinity for copper(II) ions and forms a stable chelate complex; in plasma, it functions as part of the body's natural copper transport and tissue regeneration system.

Per Pickart and Margolina's 2018 review published in International Journal of Molecular Sciences, plasma GHK levels in humans decline with age — approximately 200 ng/mL at age 20, dropping to approximately 80 ng/mL by age 60. This age-related decline is one of the proposed mechanisms underlying GHK-Cu's research applications in skin aging, wound healing, and tissue regeneration. The compound modulates expression of approximately 4,000 human genes per microarray studies cited in the same review, with effects on collagen synthesis, antioxidant defense, anti-inflammatory pathways, and stem cell activation.

GHK-Cu differs from the other peptides covered on DrawDose in two important ways. First, it is dosed at substantially higher absolute amounts — typical doses are 1 to 5 mg per administration rather than 100 to 500 mcg. Vials are typically 50 to 100 mg rather than 2 to 10 mg. Second, the published clinical literature is dominated by topical formulations (creams, serums, post-procedure applications) rather than subcutaneous injection. The injectable use covered on this page is off-label and based on community protocols rather than topical-formulation clinical trials.

GHK-Cu is widely used as a cosmetic ingredient under the INCI name "Copper tripeptide-1" and is found in commercial skincare products from multiple manufacturers. The injectable research-peptide market sells lyophilized GHK-Cu in vials for reconstitution and subcutaneous administration. The two use cases — topical cosmetic and injectable systemic — overlap in some published research but have meaningfully different clinical evidence bases.

Quick answer for the most common vial sizes

The 5 mL : 50 mg ratio documented across compounding pharmacy formulation guides for GHK-Cu produces a 10 mg/mL concentration, where every 10 units delivers 1 mg.

The math holds at any concentration. DrawDose accepts any vial size and any BAC water volume and returns the correct syringe draw for the dose entered.

The 10 mg/mL ratio is the standard for GHK-Cu because it puts the typical 1-3 mg per-injection dose at 10-30 units — easy to draw, easy to verify visually. The blue-green color of reconstituted GHK-Cu (from copper(II) coordination) is also more visible at higher concentrations, which provides a quick visual check that the peptide reconstituted correctly.

How to reconstitute lyophilized GHK-Cu

The procedure follows the standard sterile-injection prep workflow with one important difference from other peptides: GHK-Cu is light-sensitive and the reconstituted solution should be protected from prolonged light exposure.

Bring the vial and BAC water to room temperature for 15 to 20 minutes before mixing. Cold liquid hitting cold powder slows dissolution and increases the chance of clumping. Wipe both vial tops with an alcohol swab and let them dry. Draw the BAC water into a 1 mL syringe.

Insert the needle into the GHK-Cu vial at an angle so the water runs down the inside wall, not directly onto the powder pellet. Direct impingement on lyophilized peptide generates foam and can affect peptide structure. Once the water is in, swirl the vial gently for 20 to 30 seconds. Do not shake.

Properly reconstituted GHK-Cu has a distinctive blue-green color from copper(II) coordination. The color intensifies with higher concentrations (10 mg/mL solutions are visibly blue-green; 1 mg/mL solutions are pale blue). A reconstituted vial that appears colorless or that has lost color over storage indicates either that the copper has dissociated from the peptide or that the product was the free GHK tripeptide rather than the copper complex.

Why concentration determines syringe units

The relationship between vial size, BAC water, and syringe draw is fixed by concentration math. A 50 mg vial with 5 mL of water gives 10 mg/mL — every 10 units delivers 1 mg, so a 2 mg dose draws as 20 units. The same 50 mg vial with 10 mL of water gives 5 mg/mL, where 10 units delivers 0.5 mg. To hit a 2 mg target dose at 5 mg/mL, the draw is 40 units instead of 20.

Standard reconstitution practice keeps the draw between 10 and 100 units on a 1 mL insulin syringe. GHK-Cu's typical 1-3 mg per-injection dose at 10 mg/mL produces draws in the 10-30 unit range, which is the precision band. DrawDose computes this automatically; the auto-selected BAC water volume on the result panel is tuned to keep the draw in a measurable band.

Documented dosing protocols

There are no FDA-approved subcutaneous GHK-Cu dosing protocols. The copper tripeptide is FDA-approved for topical cosmetic use under the INCI designation "Copper tripeptide-1," but injectable formulations are not FDA-approved as drugs.

The most rigorous clinical data on GHK-Cu comes from topical-formulation trials. Per the Mulder et al. randomized controlled trial cited in the Archives of Facial Plastic Surgery review, topical GHK-Cu accelerated healing in diabetic plantar ulcers compared to placebo. Per the Krüger et al. pilot study referenced in the Pickart and Margolina 2018 review, twice-daily topical GHK-Cu in nano-lipid carrier over 8 weeks produced measurable increases in skin thickness, hydration, elasticity, and collagen synthesis in aged skin. Per the Miller et al. 2006 study published in Archives of Facial Plastic Surgery, topical GHK-Cu after CO2 laser resurfacing improved healing characteristics compared to controls.

Community protocol surveys aggregated from r/Peptides, r/PeptideHowTo, and clinician-published peptide guides describe injectable GHK-Cu dosing as follows.

The standard subcutaneous dose is 1 to 3 mg per injection, administered 1 to 2 times daily during active treatment phases. The most common pattern is 2 mg once daily. Some users running aggressive recovery protocols dose 3 mg twice daily for the first 2-4 weeks before tapering.

For systemic effects (longevity, general tissue regeneration), once-daily subcutaneous injection at 1-2 mg over 4-12 week cycles is documented. For specific injuries or post-surgical recovery, the loading-then-maintenance pattern (3 mg twice daily for 2-4 weeks, then 1-2 mg daily for maintenance) is documented.

For skin and hair applications, the topical route is universally preferred over injection in clinical-practice guides — the molecule's primary documented effects are local to the application site, and topical penetration via cosmetic formulations is well-characterized. Subcutaneous injection for skin-specific goals is community practice rather than evidence-based; the better-evidenced approach for cosmetic skin effects is topical.

The half-life of GHK-Cu in plasma is short (estimates in the range of minutes to a few hours), but the downstream gene expression effects extend well beyond plasma residence. This is why community protocols can dose once daily despite the short half-life.

Topical vs injectable use

This page focuses on injectable GHK-Cu reconstitution math, but the topical-versus-injectable distinction matters substantially for users deciding how to use the compound.

Topical use has the strongest published clinical evidence. Multiple controlled trials have demonstrated benefits in wound healing (diabetic ulcers, surgical wounds, post-laser-resurfacing recovery), aged skin (collagen synthesis, hydration, elasticity), and hair follicle stimulation (some early-stage research on alopecia). The mechanism is local — GHK-Cu penetrates the stratum corneum (especially in liposomal or nano-lipid carriers) and acts on dermal fibroblasts and keratinocytes.

Injectable use has thinner clinical evidence but is the route community protocols use for systemic regenerative goals. The rationale: subcutaneous injection bypasses the topical penetration barrier and allows GHK-Cu to reach tissues not accessible via skin application. Whether this rationale is correct is unproven; the published research base on injectable GHK-Cu in humans is small.

For users targeting skin or scalp benefits specifically, topical application of cosmetic-grade GHK-Cu products is the better-evidenced choice. Injectable use is appropriate for systemic regenerative goals (post-surgical recovery, broader anti-aging, joint or tendon recovery) where the topical route doesn't deliver adequate systemic exposure.

Adverse reactions and safety profile

GHK-Cu has an excellent published safety record. Per the Pickart and Margolina 2018 review, no serious adverse events have been reported in clinical trials of topical GHK-Cu across multiple indications and decades of use. The compound is naturally occurring in human plasma at ng/mL levels, and the supplemental amounts achieved through topical or injectable use remain within physiological ranges in tissues distant from the administration site.

Per the published topical-trial data, the most commonly reported adverse events were mild skin irritation at the application site, transient erythema, and rare allergic contact dermatitis. Frequency was low (single-digit percentage in most trials).

Subcutaneous community use of GHK-Cu has no controlled trial data documenting adverse reactions. Survey data from r/Peptides describes the most common subjective effects as mild injection site reactions (transient redness, soreness), occasional headache during the first week of use, and rarely a metallic taste reported within minutes of injection (consistent with copper systemic distribution).

Theoretical safety concerns relate to copper exposure. Copper is an essential trace element but produces toxicity at systemically elevated levels (Wilson's disease as the genetic example, copper poisoning as the acute-exposure example). Whether subcutaneous GHK-Cu doses reach copper-toxicity-relevant concentrations is debated; the molecule's tight chelation of copper(II) and short plasma half-life argue against accumulation, but published serum copper measurement data after subcutaneous GHK-Cu administration is limited.

Users with Wilson's disease or other copper metabolism disorders are universally contraindicated for systemic GHK-Cu in clinical-practice guidelines. Users on copper-containing supplements should avoid stacking high doses with injectable GHK-Cu to prevent compound copper exposure.

WADA prohibited status

GHK-Cu is not currently listed on the World Anti-Doping Agency Prohibited List. The compound's mechanism (gene expression modulation via copper coordination) does not fall under any current WADA prohibited category. This may change as the prohibited list updates annually; verify the current list before assuming status for any peptide.

Common reconstitution errors

Compounded peptide forums and pharmacy QA literature document a recurring set of errors specific to GHK-Cu.

Confusing GHK (free tripeptide) with GHK-Cu (copper complex). The two compounds have similar molecular weights but different colors and different biological activity. Properly reconstituted GHK-Cu is blue-green; reconstituted GHK is colorless. If a vial reconstitutes colorless when it was sold as GHK-Cu, the copper has dissociated or the product was the free peptide.

Light exposure during storage. GHK-Cu is more light-sensitive than other peptides because copper(II) photochemistry can degrade the complex. Store reconstituted vials in opaque containers or in the back of the refrigerator, never on a counter or in clear refrigerator door bins.

Using sterile water instead of bacteriostatic water for multi-dose vials. The standard 24-hour shelf life from sterile water is impractical for the multi-week dosing protocols GHK-Cu is typically used in. Bacteriostatic water with benzyl alcohol preservative gives 2-4 week shelf life and is the appropriate choice.

Trusting topical-formulation dosing protocols for injectable use. Topical GHK-Cu cosmetic concentrations (typically 0.05 to 0.5%) and injectable concentrations operate by different routes and are not directly comparable. Translating "twice daily topical" to "twice daily injectable" without considering the route difference can produce dosing errors.

Reusing reconstituted vials beyond 4 weeks. Per peptide stability literature, reconstituted GHK-Cu is more stable than many peptides (the copper coordination contributes to peptide stability) but degradation accelerates beyond 4 weeks at refrigerator temperature.

Storage and shelf life

Per peptide stability literature, reconstituted GHK-Cu stays stable for 2 to 4 weeks at 2 to 8°C (36 to 46°F) when reconstituted with bacteriostatic water and protected from light. Some sources cite 4 weeks specifically for GHK-Cu; the copper coordination contributes to peptide stability compared to many other peptides.

Lyophilized GHK-Cu stores for 24 months or longer at -20°C and 12 months or longer at 2 to 8°C, per the same stability literature. Light protection is more important for GHK-Cu than for most peptides because of the copper(II) photosensitivity. Heat exposure during shipping is the most documented threat to potency.

What to verify on a Certificate of Analysis

The COA reports the actual peptide content of a specific lot. For GHK-Cu specifically, the COA should confirm:

Net peptide weight separate from copper content. The "GHK-Cu" molecular weight (approximately 340 g/mol) includes both the tripeptide and the copper(II) ion. Some COAs report only the GHK content (approximately 340 g/mol for the free tripeptide); others report the complex weight. Verify which the vial contains and what the dose calculation references.

Purity by HPLC. 95% is the research-grade minimum the peptide industry has converged on. 98% is what most reputable vendors publish for GHK-Cu.

Copper content verification. The molar ratio of copper to tripeptide should be 1:1 in properly synthesized GHK-Cu. COAs from reputable vendors report copper content via atomic absorption spectroscopy or ICP-MS. Lower-than-expected copper content indicates incomplete coordination and reduced biological activity.

Mass spec confirmation matches the expected molecular weight (340.4 Da for the copper complex).

Documented combinations

GHK-Cu is commonly combined with BPC-157 and TB-500 in community protocols for post-surgical recovery, wound healing, and broader regenerative goals. The three-peptide stack — sometimes called the "healing trio" in community practice — addresses tissue repair through complementary mechanisms: BPC-157 at the local growth factor and gastric mucosa repair level, TB-500 at the systemic actin-sequestration and angiogenesis level, GHK-Cu at the gene expression and collagen synthesis level. Per the Vasireddi et al. 2025 systematic review on regenerative peptides, the three compounds are well-characterized individually but the triple combination has not been studied in published controlled trials.

Typical co-administration: 250 mcg BPC-157 daily, 2 mg TB-500 twice weekly, 2 mg GHK-Cu daily. All three peptides are stable in bacteriostatic water and can be drawn into separate syringes or, with appropriate compatibility checks, combined for single-injection administration.

For skin-specific protocols, GHK-Cu is often combined with topical retinoids (tretinoin, retinol) or with peptide-based topical formulations. The combinations work through complementary mechanisms — retinoids accelerate cellular turnover and collagen synthesis through retinoic acid receptor pathways, GHK-Cu modulates gene expression more broadly through copper coordination.

For hair applications, GHK-Cu is combined with topical minoxidil in some protocols, with the rationale that GHK-Cu's hair follicle effects complement minoxidil's vasodilatory mechanism. The combination is community practice rather than evidence-based; no controlled trial has compared GHK-Cu plus minoxidil to either alone.

FAQ

What does GHK-Cu actually do?

Per Pickart and Margolina's 2018 review, GHK-Cu modulates expression of approximately 4,000 human genes, with documented effects on collagen synthesis, antioxidant defense, anti-inflammatory signaling, stem cell activation, and tissue remodeling. The mechanism involves copper coordination via the tripeptide structure plus direct interaction with cellular signaling pathways. Clinically, the documented effects are wound healing acceleration, skin thickness and elasticity improvement in aged skin, and hair follicle stimulation.

Should I use topical or injectable GHK-Cu?

For skin and hair applications, the published clinical evidence favors topical formulations. Multiple randomized controlled trials demonstrate benefits at the application site. For systemic regenerative goals (post-surgical recovery, joint or tendon healing, broader anti-aging), injectable use is the route community protocols use, but the published evidence base for injectable GHK-Cu specifically is thinner than for topical use.

Why is reconstituted GHK-Cu blue-green?

The copper(II) ion coordinates to the tripeptide's nitrogen and oxygen atoms, producing the blue-green color characteristic of copper(II) complexes. The color intensifies with concentration. A reconstituted vial that appears colorless when it was sold as GHK-Cu indicates either copper dissociation or that the product was the free GHK tripeptide rather than the copper complex.

Is GHK-Cu safe long-term?

Topical GHK-Cu has decades of clinical use with an excellent safety record per the Pickart and Margolina 2018 review. Injectable GHK-Cu has thinner long-term safety data; controlled trials extend to weeks or months, not years. Theoretical concerns relate to copper exposure in users with Wilson's disease or other copper metabolism disorders, who are universally contraindicated. For users without copper metabolism issues, the published safety record is favorable but the long-term injectable data is limited.

Can GHK-Cu be combined with BPC-157 and TB-500?

Yes. The three-peptide combination is the canonical "healing trio" in community protocol surveys for post-surgical recovery and broader regenerative goals. The three compounds target tissue repair through complementary mechanisms. No controlled trial has evaluated the triple combination, but the individual safety profiles support co-administration.

Is GHK-Cu banned by WADA?

No. As of April 2026, GHK-Cu is not on the World Anti-Doping Agency Prohibited List. The compound's mechanism (gene expression modulation via copper coordination) does not fall under any current WADA prohibited category. Verify the current list annually before assuming status.

How long does GHK-Cu take to start working?

Per published topical-trial data, measurable effects on skin parameters (collagen, hydration, elasticity) typically appear within 4 to 8 weeks of consistent twice-daily topical use. Wound healing effects in trials of acute wounds typically appear within 1 to 2 weeks. Subjective effects from injectable use are reported in community surveys typically within 2 to 4 weeks of starting a protocol, though this is community-reported rather than from controlled trials.

Why do plasma GHK levels decline with age?

Per the Pickart and Margolina 2018 review, plasma GHK levels in humans decline from approximately 200 ng/mL at age 20 to approximately 80 ng/mL at age 60. The mechanism for the decline is not fully characterized but is thought to relate to age-related changes in plasma albumin and the proteolytic enzymes that liberate GHK from carrier proteins. The age-related decline is one of the proposed mechanisms underlying GHK-Cu's research applications in skin aging and tissue regeneration.